Welcome to our dedicated page for Lantheus Holdings SEC filings (Ticker: LNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lantheus Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lantheus Holdings's regulatory disclosures and financial reporting.
Lantheus Holdings, Inc. (LNTH) has agreed to be acquired by Curium US Holdings LLC through a merger in which Lantheus will become a wholly owned subsidiary of Curium’s parent. Each share of Lantheus common stock outstanding at the merger’s effective time will be converted into the right to receive $102.50 in cash, without interest, plus one contingent value right (CVR) that may pay up to an additional $12.00 in cash upon achievement of specified commercial milestones by January 1, 2031.
Lantheus stockholders will vote at a virtual-only special meeting on adopting the merger agreement, approving (on a non-binding basis) potential transaction-related compensation for named executive officers, and approving any adjournment to solicit additional proxies. The board of directors unanimously determined the merger terms are fair to stockholders, approved the merger agreement, and recommends voting FOR all proposals. If the merger closes, Lantheus stock will be delisted from Nasdaq and deregistered, and existing stockholders will no longer own an equity interest in the company but will retain their CVRs. Stockholders who do not vote for the merger may instead seek judicial “fair value” through appraisal rights under Delaware law.
Lantheus Holdings, Inc. (LNTH) reported that Ludger Dinkelborg, Head of Research and Development, had 2,536 shares of common stock withheld on 2026-08-17 to cover the exercise price or tax liability, at a reference price of $100.91 per share. After this Form 4 transaction, he directly holds 33,195 shares of Lantheus common stock. The transaction was not reported as being made under a Rule 10b5-1 trading plan.
Lantheus Holdings, Inc. (LNTH) reported that Chief Accounting Officer Kimberly Brown disposed of 463 shares of common stock on August 17, 2026, as a payment of option exercise price or tax liability by delivering or withholding securities at a reference price of $100.91 per share. Following this administrative transaction, Brown directly holds 13,263 shares of Lantheus common stock.
Farallon Capital Management, L.L.C. and related funds report beneficial ownership of Lantheus Holdings, Inc. common stock on an amended Schedule 13G. The group reports beneficial ownership of 5,583,479 Shares of common stock, representing 8.6% of the outstanding class as of June 30, 2026. The Shares are held directly by a series of investment partnerships referred to as the Farallon Funds, for which Farallon Capital Management, L.L.C. serves as investment manager. Managing members and senior managing members of the investment manager, including Hannah E. Dunn and other named individuals, report shared voting and dispositive power over these Shares through their roles with the Investment Manager and the Farallon Funds.
Lantheus Holdings reported stronger profitability for the first half of 2026, with revenue of approximately $765.5 million and net income of $193.4 million, up from $151.7 million a year earlier. Diluted EPS rose to $2.91. Results include a $59.5 million gain from the January 1, 2026 sale of the SPECT business and a favorable $31.8 million reduction in contingent consideration liabilities.
Cash and cash equivalents increased to $593.3 million at June 30, 2026, with operating cash flow of $217.3 million and no borrowings under a $750.0 million revolving credit facility; the main debt is $575.0 million of 2.625% Convertible Senior Notes due 2027. Product mix is shifting as oncology revenue from PYLARIFY declined while Neuraceq neurology revenue reached $75.1 million and DEFINITY cardiology sales increased. The FDA issued a Complete Response Letter for LNTH-2501 (Octevy) due to third-party manufacturing-facility issues, which reduced the probability of certain milestone payments and lowered contingent consideration liabilities to $65.0 million.
Lantheus Holdings reported second-quarter 2026 worldwide revenue of $388.2 million, up 2.7% year over year. GAAP net income was $75.0 million and diluted EPS was $1.11 versus $1.12 a year earlier. Adjusted diluted EPS was $1.55 versus $1.57. PYLARIFY sales were $240.4 million (down 4.1%), Neuraceq $39.6 million, and DEFINITY $88.3 million (up 5.2%). Operating income rose 13.9% to $100.2 million. Free cash flow was $89.9 million, and cash and cash equivalents reached $593.3 million with access to a $750.0 million revolver.
On August 3, 2026 Lantheus entered a definitive agreement to merge with Curium, under which Curium US Holdings LLC will acquire all outstanding shares for $102.50 per share in cash plus non-transferable CVRs for up to an additional $12.00 per share, for total potential consideration of up to $114.50 per share and a transaction value of up to approximately $8.0 billion. The board unanimously approved the deal. In connection with the pending transaction, the company is suspending its previously issued full-year 2026 financial guidance and will not host a conference call for the quarter.
Lantheus Holdings, Inc. agreed to be acquired by Curium US Holdings LLC, with a merger subsidiary combining into Lantheus so that it becomes a wholly owned subsidiary of Curium. Each outstanding share of common stock will be converted into the right to receive $102.50 per share in cash plus one contractual CVR that can pay up to $12.00 per share in cash if specified commercial milestones are achieved in its Global Prostate Cancer Diagnostics, Global Neurology Diagnostics and Global DEFINITY franchises. If completed, Lantheus common stock will be delisted from the Nasdaq Global Market and deregistered under the Exchange Act.
Closing requires a majority stockholder vote, expiration or termination of HSR and other regulatory waiting periods, absence of legal prohibitions, accuracy of representations, covenant compliance and no continuing Material Adverse Effect for Lantheus. The transaction is not subject to a financing condition; Curium has obtained equity and debt commitments. Termination fees include $385 million or a $100 million regulatory fee payable by Curium in certain cases and a $228 million fee payable by Lantheus in others. The board also approved a $6.0 million transaction bonus pool, including $4.0 million for CEO Mary Anne Heino and $500,000 for Daniel M. Niedzwiecki, and amended executive severance letters to clarify treatment of converted PSUs and eligibility for 2026 bonuses following qualifying terminations.
Lantheus Holdings agreed to be acquired by Curium US Holdings in an all‑cash merger. Curium will pay $102.50 per share in cash at closing and issue non‑transferable contingent value rights (CVRs) for up to $12.00 per share tied to future commercial milestones, for maximum consideration of $114.50 per share and total transaction value of up to approximately $8.0 billion. The price represents a 38% premium to Lantheus’ unaffected 60‑day volume‑weighted average price, with additional premiums versus other trading benchmarks.
CVR milestones are based on achieving specified 2028‑2030 aggregate sales targets across Global Prostate Cancer Diagnostics, Global Neurology Diagnostics and the Global DEFINITY business; there is expressly no assurance any CVR payments will be made. The deal, unanimously approved by Lantheus’ board after a strategic review, is expected to close in the first half of 2027, financed with a mix of debt and equity and subject to shareholder and regulatory approvals. Lantheus will remain a public company until closing, has paused its CEO search, will not host its Q2 2026 earnings call and is suspending prior full‑year 2026 guidance.
Vanguard Portfolio Management reports beneficial ownership of Lantheus Holdings Inc common stock on a Schedule 13G. The filing states beneficial ownership of 3,300,293 shares, representing 5.06% of the class, as of June 30, 2026.
Vanguard has sole voting power over 61,822 shares and sole dispositive power over all 3,300,293 shares, with no shared voting or dispositive power. The position reflects securities over which Vanguard Portfolio Management LLC and certain affiliated entities exercise dispositive and/or voting authority, including Vanguard funds and other managed accounts. No other individual person's interest in these securities exceeds 5% of the class.
Lantheus Holdings, Inc. director Gerard Ber reported a small tax-related share disposition. On May 14, 2026, 381 shares of common stock were disposed of at $96.67 per share to satisfy a tax obligation by delivering shares rather than cash.
After this tax-withholding transaction, Ber directly held 27,118 shares of Lantheus common stock. This type of Form 4 event reflects administrative handling of taxes on equity compensation rather than an open-market sale decision.